 The investigators have shown in animal studies that IDO upregulation limits tumor response to RT CpG and that addition of IDO blockade improves therapeutic efficacy. On the basis of these data, the investigators hypothesize that IDO inhibition will improve upon the known historical efficacy of RT CpG therapy, and will be highly effective and well tolerated in the management of advanced solid tumors and lymphomas. 